Tislelizumab for MSI-H or dMMR solid tumors after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer diagnosis has been confirmed by tissue testing (biopsy or surgery sample)
- Your solid tumor is MSI-H or dMMR (tests from your tumor confirm this)
- Your cancer is locally advanced but not fully removable or has spread (metastatic)
- You’ve had prior treatment for advanced disease
- You can be checked for response: at least one measurable tumor spot on scans
- Your general health is good enough (ECOG 0–1) and your organs function well enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single immunotherapy drug (tislelizumab) for people with advanced solid tumors that haven't responded to other treatments. It's for those who haven't had immunotherapy before and have a specific genetic marker in their tumor that suggests their immune system might be more active.
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
This trial tests tislelizumab given after colon cancer surgery to lower the risk of the cancer coming back. It is for people with stage II or III colon cancer that has defective mismatch repair (dMMR).
This Phase 2 trial studies whether adding tislelizumab to standard chemo (CAPOX) around the time of surgery can lower the risk of colon or rectal cancer coming back. It’s for people with stage II or III tumors that have an MSI-H or dMMR test result, which may mean they’re more likely to respond to immune-based treatment.
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
Hear when a new MSI-H/dMMR Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.